Maze Therapeutics MAZE
NASDAQ MAZE
$26.65 -0.53 (-1.95%)
At close: Oct 1, 2026 · 4:00 PM EDT

Maze Therapeutics (MAZE) Non Operating Interest Expenses (2026)

Updated

Maze Therapeutics (MAZE) posted Non Operating Interest Expenses of $931,000 for Q2 2026, up 7.5% from the prior quarter.

Analysis

Maze Therapeutics (MAZE) Non Operating Interest Expenses (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 281.00 Mn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -462.00 Mn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -435.00 Mn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 673.00 Mn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 247.00 Mn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Maze Therapeutics 1.51 Bn 1.51 Bn - 931,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 931,000.00
Mar 31, 2026 866,000.00
API Access

Maze Therapeutics Non Operating Interest Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-interest-expenses&ticker=MAZE&period=max&api_key=YOUR_API_KEY